Drug class
Erythropoiesis-stimulating Agent; Erythropoietin; Increased Erythroid Cell Production
Mechanism of action
Aranesp stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.
General use cases
- Anemia
- anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis
- anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
